Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

ClinicalTrials.gov ID: NCT00134264

Public ClinicalTrials.gov record NCT00134264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents

Study identification

NCT ID
NCT00134264
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
15,067 participants

Conditions and interventions

Interventions

  • atorvastatin Drug
  • torcetrapib/atorvastatin Drug

Drug

Eligibility (public fields only)

Age range
45 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2004
Primary completion
May 31, 2007
Completion
May 31, 2007
Last update posted
Feb 2, 2012

2004 – 2007

United States locations

U.S. sites
95
U.S. states
37
U.S. cities
95
Facility City State ZIP Site status
Pfizer Investigational Site Alabaster Alabama
Pfizer Investigational Site Birmingham Alabama
Pfizer Investigational Site Gilbert Arizona
Pfizer Investigational Site Phoenix Arizona
Pfizer Investigational Site Tucson Arizona
Pfizer Investigational Site Fresno California
Pfizer Investigational Site Los Angeles California
Pfizer Investigational Site Modesto California
Pfizer Investigational Site San Diego California
Pfizer Investigational Site Santa Rosa California
Pfizer Investigational Site Tustin California
Pfizer Investigational Site Walnut Creek California
Pfizer Investigational Site Denver Colorado
Pfizer Investigational Site Longmont Colorado
Pfizer Investigational Site Guilford Connecticut
Pfizer Investigational Site Hartford Connecticut
Pfizer Investigational Site Washington D.C. District of Columbia
Pfizer Investigational Site Clearwater Florida
Pfizer Investigational Site Coral Gables Florida
Pfizer Investigational Site Fort Meyers Florida
Pfizer Investigational Site Jacksonville Florida
Pfizer Investigational Site Jacksonville Beach Florida
Pfizer Investigational Site Lakeland Florida
Pfizer Investigational Site Orlando Florida
Pfizer Investigational Site Pensacola Florida
Pfizer Investigational Site Port Charlotte Florida
Pfizer Investigational Site Sarasota Florida
Pfizer Investigational Site West Palm Beach Florida
Pfizer Investigational Site Atlanta Georgia
Pfizer Investigational Site Aurora Illinois
Pfizer Investigational Site Blue Island Illinois
Pfizer Investigational Site Chicago Illinois
Pfizer Investigational Site Evansville Indiana
Pfizer Investigational Site Fort Wayne Indiana
Pfizer Investigational Site Davenport Iowa
Pfizer Investigational Site Des Moines Iowa
Pfizer Investigational Site Iowa City Iowa
Pfizer Investigational Site Wichita Kansas
Pfizer Investigational Site Witchita Kansas
Pfizer Investigational Site Louisville Kentucky
Pfizer Investigational Site Baton Rouge Louisiana
Pfizer Investigational Site Covington Louisiana
Pfizer Investigational Site Marrero Louisiana
Pfizer Investigational Site Scarborough Maine
Pfizer Investigational Site Baltimore Maryland
Pfizer Investigational Site Bel Air Maryland
Pfizer Investigational Site Columbia Maryland
Pfizer Investigational Site Towson Maryland
Pfizer Investigational Site Westminster Maryland
Pfizer Investigational Site Abington Massachusetts
Pfizer Investigational Site Haverhill Massachusetts
Pfizer Investigational Site Natick Massachusetts
Pfizer Investigational Site Grand Rapids Michigan
Pfizer Investigational Site Minneapolis Minnesota
Pfizer Investigational Site Saint Paul Minnesota
Pfizer Investigational Site St Louis Missouri
Pfizer Investigational Site Billings Montana
Pfizer Investigational Site Butte Montana
Pfizer Investigational Site Omaha Nebraska
Pfizer Investigational Site Papillon Nebraska
Pfizer Investigational Site Las Vegas Nevada
Pfizer Investigational Site Concord New Hampshire
Pfizer Investigational Site Lebanon New Hampshire
Pfizer Investigational Site Manchester New Hampshire
Pfizer Investigational Site Elmer New Jersey
Pfizer Investigational Site Haddon Heights New Jersey
Pfizer Investigational Site New Brunswick New Jersey
Pfizer Investigational Site Garden City New York
Pfizer Investigational Site New Hyde Park New York
Pfizer Investigational Site Rochester New York
Pfizer Investigational Site Durham North Carolina
Pfizer Investigational Site Winston-Salem North Carolina
Pfizer Investigational Site Cincinnati Ohio
Pfizer Investigational Site Cleveland Ohio
Pfizer Investigational Site Columbus Ohio
Pfizer Investigational Site Mansfield Ohio
Pfizer Investigational Site Sandusky Ohio
Pfizer Investigational Site Toledo Ohio
Pfizer Investigational Site Oklahoma City Oklahoma
Pfizer Investigational Site Portland Oregon
Pfizer Investigational Site Beaver Pennsylvania
Pfizer Investigational Site Philadelphia Pennsylvania
Pfizer Investigational Site Kingsport Tennessee
Pfizer Investigational Site Nashville Tennessee
Pfizer Investigational Site Beaumont Texas
Pfizer Investigational Site Dallas Texas
Pfizer Investigational Site Houston Texas
Pfizer Investigational Site Plano Texas
Pfizer Investigational Site San Antonio Texas
Pfizer Investigational Site Salt Lake City Utah
Pfizer Investigational Site Burlington Vermont
Pfizer Investigational Site Norfolk Virginia
Pfizer Investigational Site Richmond Virginia
Pfizer Investigational Site Burien Washington
Pfizer Investigational Site Tacoma Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 126 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00134264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2012 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00134264 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →